The hinge region: an important receptor component for GPHR function

Trends in Endocrinology and Metabolism

Volumn 21, Issue 2, 2010, Pages 111-122

  Mueller, Sandra ^a   Jaeschke, Holger ^a   Günther, Robert ^a   Paschke, Ralf ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CHORIONIC GONADOTROPIN RECEPTOR; FOLLICLE STIMULATING HORMONE RECEPTOR; GLYCOPROTEIN HORMONE RECEPTOR; HORMONE RECEPTOR; LUTEINIZING HORMONE RECEPTOR; THYROTROPIN RECEPTOR; UNCLASSIFIED DRUG;

CARBOXY TERMINAL SEQUENCE; CONFORMATIONAL TRANSITION; HORMONE BINDING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIGAND BINDING; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FAMILY; PROTEIN STRUCTURE; RECEPTOR INTRINSIC ACTIVITY; REVIEW; SIGNAL TRANSDUCTION;

AMINO ACID SEQUENCE; HUMANS; MODELS, BIOLOGICAL; MOLECULAR SEQUENCE DATA; PROTEIN FOLDING; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, FSH; RECEPTORS, LH; RECEPTORS, PITUITARY HORMONE; RECEPTORS, THYROTROPIN; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 75249105588     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tem.2009.09.001     Document Type: Review

References (84)

1. Palczewski K., et al. Crystal structure of rhodopsin: a G protein-coupled receptor. Science 289 (2000) 739-745
2. Cherezov V., et al. High-resolution crystal structure of an engineered human β2-adrenergic G protein-coupled receptor. Science 318 (2007) 1258-1265
3. Rasmussen S.G., et al. Crystal structure of the human β2 adrenergic G-protein-coupled receptor. Nature 450 (2007) 383-387
4. Fan Q.R., and Hendrickson W.A. Structure of human follicle-stimulating hormone in complex with its receptor. Nature 433 (2005) 269-277
5. Sanders J., et al. Crystal structure of the TSH receptor in complex with a thyroid-stimulating autoantibody. Thyroid 17 (2007) 395-410
6. Kleinau G., et al. Identification of a novel epitope in the thyroid-stimulating hormone receptor ectodomain acting as intramolecular signaling interface. J. Biol. Chem. 279 (2004) 51590-51600
7. Moyle W.R., et al. Model of glycoprotein hormone receptor ligand binding and signaling. J. Biol. Chem. 279 (2004) 44442-44459
8. Nunez M.R., et al. Analysis of the thyrotropin receptor-thyrotropin interaction by comparative modeling. Thyroid 14 (2004) 991-1011
9. Rapoport B., and McLachlan S.M. The thyrotropin receptor in Graves' disease. Thyroid 17 (2007) 911-922
10. Dunker A.K., et al. The unfoldomics decade: an update on intrinsically disordered proteins. BMC Genomics 9 Suppl. 2 (2008) S1
11. Rapoport B., et al. The thyrotropin (TSH) receptor: interaction with TSH and autoantibodies. Endocr. Rev. 19 (1998) 673-716
12. Bruysters M., et al. Asp330 and Tyr331 in the C-terminal cysteine-rich region of the luteinizing hormone receptor are key residues in hormone-induced receptor activation. J. Biol. Chem. 283 (2008) 25821-25828
13. Mizutori Y., et al. The thyrotropin receptor hinge region is not simply a scaffold for the leucine-rich domain but contributes to ligand binding and signal transduction. Mol. Endocrinol. 22 (2008) 1171-1182
14. Kleinau G., and Krause G. Thyrotropin and homologous glycoprotein hormone receptors: structural and functional aspects of extracellular signaling mechanisms. Endocr. Rev. 30 (2009) 133-151
15. Mueller S., et al. Significance of ectodomain cysteine boxes 2 and 3 for the activation mechanism of the thyroid-stimulating hormone receptor. J. Biol. Chem. 281 (2006) 31638-31646
16. Mueller S., et al. Extended hormone binding site of the human thyroid stimulating hormone receptor: distinctive acidic residues in the hinge region are involved in bovine thyroid stimulating hormone binding and receptor activation. J. Biol. Chem. 283 (2008) 18048-18055
17. Chen C.R., et al. A monoclonal antibody with TSH receptor inverse agonist and TSH antagonist activities binds to the receptor hinge region as well as to the leucine-rich domain. Mol. Endocrinol. 150 (2009) 3401-3408
18. Agrawal G., and Dighe R.R. Critical involvement of the hinge region of the follicle-stimulating hormone receptor in the activation of the receptor. J. Biol. Chem. 284 (2009) 2636-2647
19. Vassart G., and Dumont J.E. The thyrotropin receptor and the regulation of thyrocyte function and growth. Endocr. Rev. 13 (1992) 596-611
20. Altschul S.F., et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 25 (1997) 3389-3402
21. Ho S.C., et al. Effects of mutations involving cysteine residues distal to the S281HCC motif at the C-terminus on the functional characteristics of a truncated ectodomain-only thyrotropin receptor anchored on glycosylphosphatidyl-inositol. Thyroid 18 (2008) 1313-1319
22. Chazenbalk G.D., et al. Evidence that the thyrotropin receptor ectodomain contains not one, but two, cleavage sites. Mol. Endocrinol. 138 (1997) 2893-2899
23. Loosfelt H., et al. Two-subunit structure of the human thyrotropin receptor. Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 3765-3769
24. Tanaka K., et al. Thyrotropin receptor cleavage at site 1 involves two discontinuous segments at each end of the unique 50-amino acid insertion. J. Biol. Chem. 274 (1999) 2093-2096
25. de Bernard S., et al. Sequential cleavage and excision of a segment of the thyrotropin receptor ectodomain. J. Biol. Chem. 274 (1999) 101-107
26. Wadsworth H.L., et al. An insertion in the human thyrotropin receptor critical for high affinity hormone binding. Science 249 (1990) 1423-1425
27. Chen C.R., et al. Evidence that human thyroid cells express uncleaved, single-chain thyrotropin receptors on their surface. Mol. Endocrinol. 147 (2006) 3107-3113
28. Zhang R., et al. Requirement of cysteine residues in exons 1-6 of the extracellular domain of the luteinizing hormone receptor for gonadotropin binding. J. Biol. Chem. 271 (1996) 5755-5760
29. Nagayama Y., and Rapoport B. Role of the carboxyl-terminal half of the extracellular domain of the human thyrotropin receptor in signal transduction. Mol. Endocrinol. 131 (1992) 548-552
30. Ho S.C., et al. Effects of mutations involving the highly conserved S281HCC motif in the extracellular domain of the thyrotropin (TSH) receptor on TSH binding and constitutive activity. Mol. Endocrinol. 142 (2001) 2760-2767
31. Kosugi S., et al. Role of cysteine residues in the extracellular domain and exoplasmic loops of the transmembrane domain of the TSH receptor: effect of mutation to serine on TSH receptor activity and response to thyroid stimulating autoantibodies. Biochem. Biophys. Res. Commun. 189 (1992) 1754-1762
32. Nagayama Y., et al. Thyrotropin-luteinizing hormone/chorionic gonadotropin receptor extracellular domain chimeras as probes for thyrotropin receptor function. Proc. Natl. Acad. Sci. U. S. A. 88 (1991) 902-905
33. Duprez L., et al. Constitutive activation of the TSH receptor by spontaneous mutations affecting the N-terminal extracellular domain. FEBS Lett. 409 (1997) 469-474
34. Gruters A., et al. Severe congenital hyperthyroidism caused by a germ-line neo mutation in the extracellular portion of the thyrotropin receptor. J. Clin. Endocrinol. Metab. 83 (1998) 1431-1436
35. Kopp P., et al. Congenital hyperthyroidism caused by a solitary toxic adenoma harboring a novel somatic mutation (serine281→isoleucine) in the extracellular domain of the thyrotropin receptor. J. Clin. Invest. 100 (1997) 1634-1639
36. Jaeschke H., et al. An aromatic environment in the vicinity of serine 281 is a structural requirement for thyrotropin receptor function. Mol. Endocrinol. 147 (2006) 1753-1760
37. Nakabayashi K., et al. Activation of the luteinizing hormone receptor in the extracellular domain. Mol. Cell Endocrinol. 202 (2003) 139-144
38. Montanelli L., et al. Modulation of ligand selectivity associated with activation of the transmembrane region of the human follitropin receptor. Mol. Endocrinol. 18 (2004) 2061-2073
39. Nakabayashi K., et al. Activation of the luteinizing hormone receptor following substitution of Ser-277 with selective hydrophobic residues in the ectodomain hinge region. J. Biol. Chem. 275 (2000) 30264-30271
40. Biebermann H., et al. Mutations of the human thyrotropin receptor gene causing thyroid hypoplasia and persistent congenital hypothyroidism. J. Clin. Endocrinol. Metab. 82 (1997) 3471-3480
41. de Roux N., et al. Four families with loss of function mutations of the thyrotropin receptor. J. Clin. Endocrinol. Metab. 81 (1996) 4229-4235
42. Russo D., et al. A novel mutation in the thyrotropin (TSH) receptor gene causing loss of TSH binding but constitutive receptor activation in a family with resistance to TSH. J. Clin. Endocrinol. Metab. 85 (2000) 4238-4242
43. Camilot M., et al. Thyrotropin receptor gene mutations and TSH resistance: variable expressivity in the heterozygotes. Clin. Endocrinol. (Oxf.) 63 (2005) 146-151
44. Zhang M.L., et al. Constitutive activation of the thyrotropin receptor by deletion of a portion of the extracellular domain. Biochem. Biophys. Res. Commun. 211 (1995) 205-210
45. Stavrou S.S., et al. A novel mutation of the human luteinizing hormone receptor in 46XY and 46XX sisters. J. Clin. Endocrinol. Metab. 83 (1998) 2091-2098
46. Claus M., et al. A hydrophobic cluster in the center of the third extracellular loop is important for thyrotropin receptor signaling. Mol. Endocrinol. 146 (2005) 5197-5203
47. Chen C.R., et al. Evidence that the C terminus of the A subunit suppresses thyrotropin receptor constitutive activity. Mol. Endocrinol. 144 (2003) 3821-3827
48. Costagliola S., et al. Tyrosine sulfation is required for agonist recognition by glycoprotein hormone receptors. EMBO J. 21 (2002) 504-513
49. Bonomi M., et al. Structural differences in the hinge region of the glycoprotein hormone receptors: evidence from the sulfated tyrosine residues. Mol. Endocrinol. 20 (2006) 3351-3363
50. Nagayama Y., et al. Identification of the sites of asparagine-linked glycosylation on the human thyrotropin receptor and studies on their role in receptor function and expression. J. Pharmacol. Exp. Ther. 295 (2000) 404-409
51. Davis D., et al. Identification of the sites of N-linked glycosylation on the follicle-stimulating hormone (FSH) receptor and assessment of their role in FSH receptor function. Mol. Endocrinol. 9 (1995) 159-170
52. Sangkuhl K., et al. Structural requirements for mutational lutropin/choriogonadotropin receptor activation. J. Biol. Chem. 277 (2002) 47748-47755
53. Zeng H., et al. The role of the hinge region of the luteinizing hormone receptor in hormone interaction and signal generation. J. Biol. Chem. 276 (2001) 3451-3458
54. Martens J.W., et al. Mutant luteinizing hormone receptors in a compound heterozygous patient with complete Leydig cell hypoplasia: abnormal processing causes signaling deficiency. J. Clin. Endocrinol. Metab. 87 (2002) 2506-2513
55. Huang J., and Puett D. Identification of two amino acid residues on the extracellular domain of the lutropin/choriogonadotropin receptor important in signaling. J. Biol. Chem. 270 (1995) 30023-30028
56. Gromoll J., et al. Male hypogonadism caused by homozygous deletion of exon 10 of the luteinizing hormone (LH) receptor: differential action of human chorionic gonadotropin and LH. J. Clin. Endocrinol. Metab. 85 (2000) 2281-2286
57. Muller T., et al. Absence of exon 10 of the human luteinizing hormone (LH) receptor impairs LH, but not human chorionic gonadotropin action. J. Clin. Endocrinol. Metab. 88 (2003) 2242-2249
58. Davis D.P., et al. The six N-linked carbohydrates of the lutropin/choriogonadotropin receptor are not absolutely required for correct folding, cell surface expression, hormone binding, or signal transduction. Mol. Endocrinol. 11 (1997) 550-562
59. Dallas J.S., et al. Thyrotropin (TSH) interacts with multiple discrete regions of the TSH receptor: polyclonal rabbit antibodies to one or more of these regions can inhibit TSH binding and function. Mol. Endocrinol. 134 (1994) 1437-1445
60. Jeffreys J., et al. Characterization of the thyrotropin binding pocket. Thyroid 12 (2002) 1051-1061
61. Johnstone A.P., et al. A functional site on the human TSH receptor: a potential therapeutic target in Graves' disease. Clin. Endocrinol. (Oxf.) 59 (2003) 437-441
62. Kosugi S., et al. Site-directed mutagenesis of a portion of the extracellular domain of the rat thyrotropin receptor important in autoimmune thyroid disease and nonhomologous with gonadotropin receptors. Relationship of functional and immunogenic domains. J. Biol. Chem. 266 (1991) 19413-19418
63. Morris J.C., et al. Structure-function studies of the human thyrotropin receptor. Inhibition of binding of labeled thyrotropin (TSH) by synthetic human TSH receptor peptides. J. Biol. Chem. 268 (1993) 10900-10905
64. Shepherd P.S., et al. Identification of an important thyrotrophin binding site on the human thyrotrophin receptor using monoclonal antibodies. Mol. Cell Endocrinol. 149 (1999) 197-206
65. Chazenbalk G.D., et al. Engineering the human thyrotropin receptor ectodomain from a non-secreted form to a secreted, highly immunoreactive glycoprotein that neutralizes autoantibodies in Graves' patients' sera. J. Biol. Chem. 272 (1997) 18959-18965
66. Mueller S., et al. The superagonistic activity of bovine thyroid-stimulating hormone (TSH) and the human TR1401 TSH Analog is determined by specific amino acids in the hinge region of the human TSH receptor. J. Biol. Chem. 284 (2009) 16317-16324
67. Szkudlinski M.W., et al. Engineering human glycoprotein hormone superactive analogues. Nat. Biotechnol. 14 (1996) 1257-1263
68. Thomas D., et al. Mutational analyses of the extracellular domain of the full-length lutropin/choriogonadotropin receptor suggest leucine-rich repeats 1-6 are involved in hormone binding. Mol. Endocrinol. 10 (1996) 760-768
69. Braun T., et al. Amino-terminal leucine-rich repeats in gonadotropin receptors determine hormone selectivity. EMBO J. 10 (1991) 1885-1890
70. Bernard M.P., et al. Lutropins appear to contact two independent sites in the extracellular domain of their receptors. Biochem. J. 335 (1998) 611-617
71. Ando T., et al. Thyrotropin receptor antibodies: new insights into their actions and clinical relevance. Best Pract. Res. Clin. Endocrinol. Metab. 19 (2005) 33-52
72. Davies T.F., et al. Thyrotropin receptor-associated diseases: from adenomata to Graves disease. J. Clin. Invest. 115 (2005) 1972-1983
73. Sanders J., et al. Characteristics of a human monoclonal autoantibody to the thyrotropin receptor: sequence structure and function. Thyroid 14 (2004) 560-570
74. Chen C.R., et al. Suppression of thyrotropin receptor constitutive activity by a monoclonal antibody with inverse agonist activity. Mol. Endocrinol. 148 (2007) 2375-2382
75. Chen C.R., et al. Identification of key amino acid residues in a thyrotropin receptor monoclonal antibody epitope provides insight into its inverse agonist and antagonist properties. Mol. Endocrinol. 149 (2008) 3427-3434
76. Jaschke H., et al. A low molecular weight agonist signals by binding to the transmembrane domain of thyroid-stimulating hormone receptor (TSHR) and luteinizing hormone/chorionic gonadotropin receptor (LHCGR). J. Biol. Chem. 281 (2006) 9841-9844
77. Neumann S., et al. Small-molecule agonists for the thyrotropin receptor stimulate thyroid function in human thyrocytes and mice. Proc. Natl. Acad. Sci. U. S. A. 106 (2009) 12471-12476
78. Kleinau G., et al. Implications for molecular mechanisms of glycoprotein hormone receptors using a new sequence-structure-function analysis resource. Mol. Endocrinol. 21 (2007) 574-580
79. Ishida T., and Kinoshita K. Prediction of disordered regions in proteins based on the meta approach. Bioinformatics 24 (2008) 1344-1348
80. Akamizu T., et al. Chimeric studies of the extracellular domain of the rat thyrotropin (TSH) receptor: amino acids (268-304) in the TSH receptor are involved in ligand high affinity binding, but not in TSH receptor-specific signal transduction. Endocr. J. 40 (1993) 363-372
81. Kosugi S., et al. The extracellular domain of the TSH receptor has an immunogenic epitope reactive with Graves' IgG but unrelated to receptor function as well as determinants having different roles for high affinity TSH binding and the activity of thyroid-stimulating autoantibodies. Thyroid 1 (1991) 321-330
82. Kosugi S., et al. Further characterization of a high affinity thyrotropin binding site on the rat thyrotropin receptor which is an epitope for blocking antibodies from idiopathic myxedema patients but not thyroid stimulating antibodies from Graves' patients. Biochem. Biophys. Res. Commun. 180 (1991) 1118-1124
83. Ho S.C., et al. Cysteine 390 mutation of the TSH receptor modulates its ectodomain as an inverse agonist on the serpentine domain with decrease in basal constitutive activity. Mol. Cell. Endocrinol. 245 (2005) 158-168
84. Allen L.A., et al. A novel loss of function mutation in exon 10 of the FSH receptor gene causing hypergonadotrophic hypogonadism: clinical and molecular characteristics. Hum. Reprod. 18 (2003) 251-256